Safety and Efficacy Study of EPI-743 (Vincerinone™) on Visual Function in Patients with Friedreich’s Ataxia

Kelly L. Sullivan

Safety and Efficacy Study of EPI-743 (Vincerinone™) on Visual Function in Patients with Friedreich’s Ataxia

Kelly L. Sullivan

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Other contribution › Other

Original language	American English
State	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Epidemiology
Public Health

Cite this

@misc{67311ff0f19b40b29b0925fe4d729391,

title = "Safety and Efficacy Study of EPI-743 (Vincerinone{\texttrademark}) on Visual Function in Patients with Friedreich{\textquoteright}s Ataxia",

author = "Sullivan, \{Kelly L.\}",

note = "Kelly L. Sullivan(Coordinator), {"}Safety and Efficacy Study of EPI-743 (Vincerinone{\texttrademark}) on Visual Function in Patients with Friedreich{\textquoteright}s Ataxia,{"} Edison Pharmaceuticals, Inc. (2012-present).",

year = "2012",

language = "American English",

type = "Other",

}

TY - GEN

T1 - Safety and Efficacy Study of EPI-743 (Vincerinone™) on Visual Function in Patients with Friedreich’s Ataxia

AU - Sullivan, Kelly L.

N1 - Kelly L. Sullivan(Coordinator), "Safety and Efficacy Study of EPI-743 (Vincerinone™) on Visual Function in Patients with Friedreich’s Ataxia," Edison Pharmaceuticals, Inc. (2012-present).

PY - 2012

Y1 - 2012

M3 - Other

ER -